CONMED (NYSE: CNMD) EVP granted 17,198 RSUs after award correction

Rhea-AI Filing Summary

Lalomia Brent reported acquisition or exercise transactions in this Form 4 filing.

CONMED Corporation reported that Executive VP RA, QA Brent Lalomia received a corrected grant of 17,198 restricted stock units (RSUs) under the company’s 2025 Long-Term Incentive Plan. Each RSU represents one share of common stock, vesting 33% after one year, 33% after two years, and 34% after three years.

The filing explains that this amended Form 4 updates the originally reported 9,554 RSUs to include a special award of 7,644 additional RSUs, bringing the total grant to 17,198 units.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Lalomia Brent

Role Executive VP RA, QA

Type	Security	Shares	Price	Value
Grant/Award	RSUs (Restricted Stock Units)	17,198	$0.00	--

Holdings After Transaction: RSUs (Restricted Stock Units) — 17,198 shares (Direct)

Footnotes (1)

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock, par value $0.01 per share of CONMED Corporation (the "Company") and will be subject to the terms and conditions of the Company's 2025 Long-Term Incentive Plan, with the RSUs generally vesting over a three-year period with the first 33% of the RSUs vesting one year after the grant date, 33% second year and 34% third year. This Form 4/A is filed solely to correct the amount of RSUs granted. A special award of 7,644 shares was awarded in addition to the originally reported 9,554 shares for a total of 17,198 RSUs granted.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lalomia Brent

(Last) (First) (Middle)

C/O CONMED CORPORATION

11311 CONCEPT BOULEVARD

(Street)

LARGO FL 33773

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CONMED Corp [ CNMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Executive VP RA, QA

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)
03/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
RSUs (Restricted Stock Units)	$0	03/02/2026		A		17,198		(1)	03/02/2036	Common Stock	17,198(2)	$0	17,198	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock, par value $0.01 per share of CONMED Corporation (the "Company") and will be subject to the terms and conditions of the Company's 2025 Long-Term Incentive Plan, with the RSUs generally vesting over a three-year period with the first 33% of the RSUs vesting one year after the grant date, 33% second year and 34% third year.

2. This Form 4/A is filed solely to correct the amount of RSUs granted. A special award of 7,644 shares was awarded in addition to the originally reported 9,554 shares for a total of 17,198 RSUs granted.

	/s/ Thomas Fistek for Brent Lalomia by Power of Attorney	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did CONMED (CNMD) report in this Form 4/A?

CONMED reported an amended insider transaction where Executive VP RA, QA Brent Lalomia received a grant of 17,198 restricted stock units. The amendment corrects a previously reported RSU amount and reflects the full equity award now outstanding.

How many RSUs did CONMED (CNMD) grant to Brent Lalomia?

CONMED granted Brent Lalomia a total of 17,198 restricted stock units. This includes an original award of 9,554 RSUs plus a special award of 7,644 RSUs, as clarified in the amended Form 4/A footnote disclosure.

What is the vesting schedule for Brent Lalomia’s 17,198 CONMED RSUs?

The 17,198 RSUs generally vest over three years. According to the filing, 33% vest one year after the grant date, another 33% vest in the second year, and the remaining 34% vest in the third year, subject to plan terms.

Why did CONMED file an amended Form 4/A for Brent Lalomia?

The amended Form 4/A was filed solely to correct the amount of RSUs granted. A special award of 7,644 additional RSUs was included, raising the total from the originally reported 9,554 RSUs to 17,198 RSUs granted to Brent Lalomia.

What does each CONMED (CNMD) RSU granted to Brent Lalomia represent?

Each restricted stock unit granted to Brent Lalomia represents a contingent right to receive one share of CONMED common stock. The RSUs are governed by the company’s 2025 Long-Term Incentive Plan and follow the three-year vesting schedule described in the filing.

What role does Brent Lalomia hold at CONMED (CNMD) in this filing?

In this filing, Brent Lalomia is identified as an officer of CONMED serving as Executive Vice President, Regulatory Affairs and Quality Assurance. The RSU award reflects equity-based compensation associated with this executive leadership role at the company.